The cellular pathways and potential therapeutics of polycystic kidney disease
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractPolycystic Kidney Disease (PKD) refers to a group of disorders, driven by the formation of cysts in renal tubular cells and is currently one of the leading causes of end-stage renal disease. The range of symptoms observed in PKD is due to mutations in cilia-localising genes, resulting in changes in cellular signalling. As such, compounds that are currently in preclinical and clinical trials target some of these signalling pathways that are dysregulated in PKD. In this review, we highlight these pathways including cAMP, EGF and AMPK signalling and drugs that target them and may show promise in lessening the disease burden of PKD patients. At present, tolvaptan is the only approved therapy for ADPKD, however, it carries several adverse side effects whilst comparatively, no pharmacological drug is approved for ARPKD treatment. Aside from this, drugs that have been the subject of multiple clinical trials such as metformin, which targets AMPK signalling and somatostatins, which target cAMP signalling have shown great promise in reducing cyst formation and cellular proliferation. This review also discusses other potential and novel targets that can be used for future interventions, such as β-catenin and TAZ, where research has shown that a reduction in the overexpression of these signalling components results in amelioration of disease phenotype. Thus, it becomes apparent that welldesigned preclinical investigations and future clinical trials into these pathways and other potential signalling targets are crucial in bettering disease prognosis for PKD patients and could lead to personalised therapy approaches.
CitationRichards, T., Modarage, K., Malik, S.A. and Goggolidou, P. (2021) The cellular pathways and potential therapeutics of polycystic kidney disease. Biochemical Society Transactions, 49 (3), pp. 171–1188.
JournalBiochemical Society Transactions
PubMed ID34156429 (pubmed)
DescriptionThis is an accepted manuscript of an article published by Portland Press in Biochemical Society Transactions on 22/06/2021, available online: https://doi.org/10.1042/BST20200757 The accepted version of the publication may differ from the final published version.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/
- The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
- Authors: Richards T, Modarage K, Malik SA, Goggolidou P
- Issue date: 2021 Jun 30
- Cilia and polycystic kidney disease.
- Authors: Ma M
- Issue date: 2021 Feb
- TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
- Authors: Olalekan K, Fox A, Gilbert R
- Issue date: 2016 Sep
- Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
- Authors: Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D
- Issue date: 2018 Mar